Pain Drink, Inc. – Trademark Portfolio

Entity Type: 03

Pain Drink, Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 32 (Light Beverages) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include RHELIEF, TAME YOUR PAIN, and DR. RIGGS' RHELIEF PM. The owner is based in Las Vegas, NV.

Suite 300

Las Vegas, NV 89128

10 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Pain Drink, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

32
Light Beverages (4 filings)

Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages

Frequently Asked Questions

How many trademarks does Pain Drink, Inc. have?

Pain Drink, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned, 3 cancelled.

What trademark classes does Pain Drink, Inc. file in?

Pain Drink, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 32 (Light Beverages). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Pain Drink, Inc.'s most well-known trademarks?

Pain Drink, Inc.'s registered trademark portfolio includes well-known marks such as RHELIEF, TAME YOUR PAIN, and DR. RIGGS' RHELIEF PM. These are among 3 currently registered trademarks in the portfolio.

What is Pain Drink, Inc.'s trademark registration success rate?

Pain Drink, Inc. has a 30% trademark registration rate, with 3 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.